NDV HUJ

Drug Profile

NDV HUJ

Alternative Names: OV-001; TV-7000

Latest Information Update: 11 Aug 2011

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 11 Jul 2006 Final results from a phase I/II clinical trial in patients with glioblastoma multiforme have been added to the adverse events and Cancer therapeutic trials sections
  • 26 Jul 2005 OVCure is now called Theravir Management
  • 07 Jul 2004 Phase-I/II clinical trials in Glioblastoma in Israel (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top